Aurexis® in Cystic Fibrosis Subjects Chronically Colonized With Staphylococcus Aureus in Their Lungs

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE2

Total Enrollment

30 participants

Study Classification

INTERVENTIONAL

Study Start Date

2005-04-30

Study Completion Date

2006-06-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Patients who are at least 7 years old with stable Cystic Fibrosis who have Staphylococcus aureus in their Lungs will be enrolled into the study and receive one dose of Aurexis® intravenously on Study Day 1, and will be followed until Study Day 57. Aurexis is a humanized monoclonal antibody that is designed to combat Staphylococcus aureus.

The purpose of this study is to assess the safety and pharmacokinetic profile (concentration of Aurexis in blood and sputum) of Aurexis. Additionally, certain tests and measurements will be conducted to preliminarily determine if Aurexis demonstrates any benefit to these patients.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Study With Phage for CF Subjects With Pseudomonas Lung Infection

NCT06998043

Chronic Pseudomonas Aeruginosa Infection Cystic Fibrosis (CF)

RECRUITING PHASE2

Study to Evaluate Arikace™ in CF Patients With Chronic Infection Due to Pseudomonas Aeruginosa

NCT01315691

Cystic Fibrosis

WITHDRAWN PHASE3

Nebulized Bacteriophage Therapy in Cystic Fibrosis Patients With Chronic Pseudomonas Aeruginosa Pulmonary Infection

NCT05010577

Chronic Pseudomonas Aeruginosa Infection Cystic Fibrosis

COMPLETED PHASE1/PHASE2

Safety/Tolerability Study of Arikayce™ in Cystic Fibrosis Patients With Chronic Infection Due to Pseudomonas Aeruginosa

NCT00558844

Cystic Fibrosis

COMPLETED PHASE1/PHASE2

Study to Evaluate the Effect of KB001-A on Time-to-Need for Antibiotic Treatment

NCT01695343

Cystic Fibrosis

COMPLETED PHASE2

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Staphylococcus Aureus

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NON_RANDOMIZED

Intervention Model

SINGLE_GROUP

Primary Study Purpose

PREVENTION

Blinding Strategy

NONE

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Aurexis® (tefibazumab)

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Male or female, ages \> 7 years old

* Diagnosis of CF as evidenced by sweat chloride test and/or genetic mutation testing
* Sputum SA CFUs \> 10,000 per mL
* Ability to expectorate sputum
* Ability to tolerate nasal lavage and collection of breath condensate
* Willing to practice reliable birth control measures during the entire study period, if subject is of childbearing potential
* Informed consent obtained from subject or legal guardian, and assent if appropriate

Exclusion Criteria

* Burkholderia cepacia in sputum

* Subjects who have had changes to their treatment regimen for CF in the past 6 weeks

* Subjects can be screened 6 weeks after IV antibiotic completion
* Subjects can be screened 7 days after oral antibiotic completion
* Received an investigational drug within 30 days of study entry
* Received any immune globulin or blood product within 30 days of study entry
* History of hypersensitivity to immune globulin preparations
* Undergoing any type of dialysis or expected to start dialysis within 30 days
* Pregnant or nursing females
* Considered unlikely to comply with the study procedures or to return for scheduled post-treatment evaluations

Minimum Eligible Age

7 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No